EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sexual function after prostate cancer surgery or radiotherapy in an international registry

Y Hess-Busch iD, C Darr iD, L Püllen, M Al-Nader iD, M Wahl, A V Bailey iD, H Wilhalme, J Lee iD, B Hadaschik, J Hess iD, TrueNTH Global Registry

BJU International · 2026-12 · 138 (6) · 1092-1103

DOI: 10.1111/bju.70431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, online erschienen am 26.08.2026. Verfasst von Y Hess-Busch und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department for Oncology, Kliniken Essen-Mitte, Essen, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy, Erectile Dysfunction, Sexual Dysfunction, Physiological. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Movember Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Our objective was to evaluate patient‐reported sexual function (SF) outcomes and sexual aid use 12 months after curative treatment for prostate cancer (PC). Patients & Methods This prospective registry‐based cohort study analysed men with localized or locally advanced PC enrolled in the TrueNTH Global Registry. Patients with baseline and 12‐month patient‐reported outcome measures after radical prostatectomy (RP), external beam radiotherapy (EBRT) ± androgen‐deprivation therapy (ADT), or brachytherapy (BT) were included. SF was assessed using the EPIC‐26 sexual function domain score (SFDS). Baseline and 12‐month EPIC‐26 SFDS were compared by treatment group, with additional analyses among RP patients examining outcomes by intent to nerve spare and sexual aid use. Linear regression, adjusted for age, National Comprehensive Cancer Network risk group, baseline SFDS, and intent to nerve spare was used to identify predictors of 12‐month SFDS among surgery patients.

Results

Overall, 13 413 men were analysed (RP 85.2%, EBRT only 9.1%, EBRT+ADT 4.3%, BT 1.3%). SF declined significantly across all modalities. Median SFDS reduction was greatest after RP (−60.0%) and smallest after BT (−40.2%). At 12 months, poor or absent erectile function was reported by 63.6–91.8% of patients, highest after RP and EBRT+ADT. Sexual aid use increased after treatment but remained low overall. Given the retrospective design and non‐representative sites in an international registry setting, these findings should be interpreted as associational rather than causal because of the potential for unmeasured confounding and cross‐country heterogeneity in treatment selection.

Conclusion

All curative PC treatments were associated with substantial deterioration in SF. These findings support enhanced pre‐treatment counselling and early integration of proactive management and structured sexual rehabilitation into survivorship care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatectomyErectile DysfunctionSexual Dysfunction, PhysiologicalHumansMaleRegistriesAgedMiddle AgedProspective StudiesBrachytherapyPatient Reported Outcome MeasuresAndrogen Antagonists

Stichwörter der Autor:innen

erectile dysfunctionpatient‐reported outcomesprostate cancerradical prostatectomyradiotherapysexual function

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • Department for Oncology, Kliniken Essen-Mitte, Essen, Germany.
  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
  • Department for Urology, University Medicine Essen, University Duisburg-Essen, Essen, Germany.
  • Departments of Urology, OBGYN, & Surgery, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
  • Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.

ORCID-Profile: Y Hess-Busch, C Darr, M Al-Nader, A V Bailey, J Lee, J Hess

Förderung

  • Movember Foundation

Zitieren

APA

Hess-Busch, Y., Darr, C., Püllen, L., Al-Nader, M., Wahl, M., Bailey, A. V., Wilhalme, H., Lee, J., Hadaschik, B., Hess, J., & TrueNTH Global Registry (2026). Sexual function after prostate cancer surgery or radiotherapy in an international registry. BJU International, 138(6), 1092-1103. https://doi.org/10.1111/bju.70431

Vancouver

Hess-Busch Y, Darr C, Püllen L, Al-Nader M, Wahl M, Bailey AV, et al. Sexual function after prostate cancer surgery or radiotherapy in an international registry. BJU International. 2026;138(6):1092-1103. doi:10.1111/bju.70431

BibTeX
@article{HessBusch2026,
  author = {Hess-Busch, Y and Darr, C and Püllen, L and Al-Nader, M and Wahl, M and Bailey, A V and Wilhalme, H and Lee, J and Hadaschik, B and Hess, J and TrueNTH Global Registry, TrueNTH Global Registry},
  title = {Sexual function after prostate cancer surgery or radiotherapy in an international registry},
  journal = {BJU International},
  year = {2026},
  volume = {138},
  number = {6},
  pages = {1092--1103},
  doi = {10.1111/bju.70431}
}
Kostenlos starten →